Yamamoto, R.; Kataoka, N.; Imamura, T.; Izumida, T.; Kinugawa, K.
PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients. J. Clin. Med. 2024, 13, 510.
https://doi.org/10.3390/jcm13020510
AMA Style
Yamamoto R, Kataoka N, Imamura T, Izumida T, Kinugawa K.
PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients. Journal of Clinical Medicine. 2024; 13(2):510.
https://doi.org/10.3390/jcm13020510
Chicago/Turabian Style
Yamamoto, Riona, Naoya Kataoka, Teruhiko Imamura, Toshihide Izumida, and Koichiro Kinugawa.
2024. "PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients" Journal of Clinical Medicine 13, no. 2: 510.
https://doi.org/10.3390/jcm13020510
APA Style
Yamamoto, R., Kataoka, N., Imamura, T., Izumida, T., & Kinugawa, K.
(2024). PR Interval as a Novel Therapeutic Target of Ivabradine Therapy—Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients. Journal of Clinical Medicine, 13(2), 510.
https://doi.org/10.3390/jcm13020510